Earnings Sentiment

Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.

Please consider a small donation if you think this website provides you with relevant information  

    

Sentiment Distribution

   

Earnings Call Transcript Word Cloud

     

Bullish Statements during Earnings call

Statement
Having the volume to do that and the financial stability of the cash generating business changes the decision-making process for such purchases and subsequently improves our business economics
As you saw in our filings, we grew revenues by almost 30% from the previous quarter and doubled year-over-year from Q3 of last year
One of the things I'm proud of -- proud about is that management and indeed the entire team treats every dollar as if it's coming out of their own pockets
I believe that the combination of our story of continued financial success and growth and the expansion of the audience that hears the story will create a multiplying impact for our shareholders
This cash burn reduction was accomplished by a combination of restructuring operational initiatives that saved a lot of money, and of course, in addition to our revenue growth, we generated positive cash margins -- generated positive margins and cash
With a total available market potential for some of our products, for example, HemeScreen, at approximately $400 million a year, there is tremendous growth potential
This is, of course, very exciting for our company, in particular to reach this point at such low revenue numbers
By purchasing various pieces of equipment over time, we can reduce our manufacturing cost and increasing margin, generating a positive ROI from those equipment purchases within less than 12 months
We believe that with minor marketing efforts costing less than $100,000 for the entire year, we can significantly boost product awareness and generate additional product sales for our products
So, overall we had a good quarter and we are continuing to head in the right direction
This is an astounding -- outstanding accomplishment for our company, and it's important to emphasize that this was not a fat cutting exercise
I'm really excited to see and share with you the results of the year-end and especially for next year as we turn the corner on delivering on Precipio's vision
Reaching financial independence and beginning to generate cash will be an exciting milestone from my vantage point, but we are well within reach of achieving that target
Since many of these are tied to revenues, the impact will continue to improve as we grow our business
This is a very meaningful jump for us in business volume and was driven both by our Pathology business as well as our Product business
We're working on several strategies and partnerships that will significantly accelerate the growth of our products revenues
With our current pipeline, we are well on our way to reaching that target
That mindset has enabled us to look at our operations closely and find ways to operate in a more cash-efficient manner, generating the same and even better results while spending less cash
The second target we achieved is a significant reduction in our expenses through the execution of various operational efficiencies as we've discussed
Depending on the revenue level and case mix, this billing and collections initiative and subsequent reduction in billing expenses yields savings of about between $50,000 to $75,000 in cash every month
I want to thank you for attending the call today, and I wish you and your families a happy Thanksgiving and a happy holiday season at the year-end
Thank you, and have a nice evening
And what it means is that in a relatively low budget and with tremendous flexibility, we can develop future products without the significant need of capital
Number one, financial stability
First of all, having a pathology division that is breakeven essentially means we have achieved a significant component of our business model which is to create a cost-free R&D center
This is just one initiative of many, which in combination have enabled us to significantly slash our cash burden
As you know, the company's strategy is to develop and sell diagnostic products that make labs better
Perhaps the most important part of the equation is that we believe we have enough cash to get us to the target, whether -- and whether it takes one or two more quarters to get there, we have the gas in the tank to reach our goal of financial independence
We've always maintained clear visibility and transparency within the entire organization as it relates to cash management, and we intend to keep it that way to ensure that the numbers continue to trend in the right direction
We like that business model
       

Bearish Statements during earnings call

Statement
Additionally, our cash burn dropped to around $1 million in the quarter, down to approximately 40% of the $2.5 million, which was our cash burn in the same quarter of last year
While our Product division has not yet reached its targets as of Q3, the combination of achieving the two other targets has effectively reduced the company breakeven threshold for Product division from $8 million to $6 million or $1.5 million per quarter
Up until now, we've been very limited in spending to enable us to reach this milestone of cash flow breakeven
The questions about our company's ability to execute, reach cash flow positive, and grow the product business will have largely been addressed
These are just a few of the impacts we will see once the company reaches cash flow breakeven
Risks and uncertainties that could cause our actual results to differ materially from those set forth in any forward-looking statements include, but are not limited to, the matters listed under risk factors in our annual report on Form 10-K for the year ended December 31, 2022, which is on file with the Securities Exchange Commission, as well as other risks detailed in our subsequent filings with the Securities and Exchange Commission
Yet another impact is the ability to invest in our product production line
This has significant implications for our future business, and I'll come back to that in a few minutes
But the important part is the most expensive part of our business, our pathology services operation, is no longer a cash drain on the company
   

Please consider a small donation if you think this website provides you with relevant information